Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1992 3
1993 10
1994 5
1995 11
1996 18
1997 35
1998 53
1999 61
2000 68
2001 96
2002 105
2003 116
2004 111
2005 85
2006 110
2007 97
2008 133
2009 116
2010 102
2011 100
2012 102
2013 72
2014 86
2015 84
2016 88
2017 65
2018 81
2019 77
2020 87
2021 81
2022 94
2023 79
2024 33

Text availability

Article attribute

Article type

Publication date

Search Results

2,258 results

Results by year

Filters applied: . Clear all
Page 1
New glaucoma medications: latanoprostene bunod, netarsudil, and fixed combination netarsudil-latanoprost.
Mehran NA, Sinha S, Razeghinejad R. Mehran NA, et al. Eye (Lond). 2020 Jan;34(1):72-88. doi: 10.1038/s41433-019-0671-0. Epub 2019 Nov 6. Eye (Lond). 2020. PMID: 31695162 Free PMC article. Review.
Three new drugs (latanoprostene bunod 0.24%, netarsudil 0.02%, and fixed combination netarsudil 0.02% -latanoprost 0.005%) have been introduced recently in the market with novel mechanisms of action. ...
Three new drugs (latanoprostene bunod 0.24%, netarsudil 0.02%, and fixed combination netarsudil 0.02% -latanoprost 0.005%) have been …
How latanoprost changed glaucoma management.
Cordeiro MF, Gandolfi S, Gugleta K, Normando EM, Oddone F. Cordeiro MF, et al. Acta Ophthalmol. 2024 Mar;102(2):e140-e155. doi: 10.1111/aos.15725. Epub 2023 Jun 23. Acta Ophthalmol. 2024. PMID: 37350260 Review.
Topical medical therapy represents the treatment of choice for many glaucoma patients. Introduction of latanoprost, 25 years ago, with an entirely new mechanism of action from that of the antiglaucoma drugs used up to that time was a very important milestone. ...The object …
Topical medical therapy represents the treatment of choice for many glaucoma patients. Introduction of latanoprost, 25 years ago, wit …
Latanoprost and pigmentation.
Grierson I, Jonsson M, Cracknell K. Grierson I, et al. Jpn J Ophthalmol. 2004 Nov-Dec;48(6):602-12. doi: 10.1007/s10384-004-0110-y. Jpn J Ophthalmol. 2004. PMID: 15592791 Review.
Latanoprost is a prostaglandin analogue with well-established efficacy in the treatment of open-angle glaucoma and ocular hypertension. ...All available evidence from in vitro, in vivo, and clinical studies suggests that latanoprost does not induce melanocyte prolif …
Latanoprost is a prostaglandin analogue with well-established efficacy in the treatment of open-angle glaucoma and ocular hypertensio …
[Long-term use of latanoprost in the treatment of glaucoma].
Kurysheva NI. Kurysheva NI. Vestn Oftalmol. 2020;136(2):125-132. doi: 10.17116/oftalma2020136021125. Vestn Oftalmol. 2020. PMID: 32366080 Review. Russian.
The present review shows that latanoprost is the most balanced prostaglandin analogue in terms of efficacy-safety. ...The review also reveals the possibility of long-term (more than five years) use of the drug, as well as effective combined treatment using latanoprost …
The present review shows that latanoprost is the most balanced prostaglandin analogue in terms of efficacy-safety. ...The review also …
Latanoprost-induced Skin Hypopigmentation.
Muñoz-Negrete FJ, Arnalich-Montiel F, Lara-Medina FJ, Rebolleda G. Muñoz-Negrete FJ, et al. J Glaucoma. 2018 Mar;27(3):e72. doi: 10.1097/IJG.0000000000000878. J Glaucoma. 2018. PMID: 29334483 No abstract available.
Fixed combination netarsudil-latanoprost for the treatment of glaucoma and ocular hypertension.
Sinha S, Lee D, Kolomeyer NN, Myers JS, Razeghinejad R. Sinha S, et al. Expert Opin Pharmacother. 2020 Jan;21(1):39-45. doi: 10.1080/14656566.2019.1685499. Epub 2019 Oct 30. Expert Opin Pharmacother. 2020. PMID: 31663782 Review.
Rho-kinase (ROCK) inhibitors are a new class of glaucoma medications introduced recently with novel mechanisms of action and favorable safety profiles. Latanoprost, a common first line drug used for treatment of glaucoma, does not adequately control pressures in all cases. …
Rho-kinase (ROCK) inhibitors are a new class of glaucoma medications introduced recently with novel mechanisms of action and favorable safet …
Latanoprost and cholinergic agonists in combination.
Toris CB, Alm A, Camras CB. Toris CB, et al. Surv Ophthalmol. 2002 Aug;47 Suppl 1:S141-7. doi: 10.1016/s0039-6257(02)00309-0. Surv Ophthalmol. 2002. PMID: 12204711 Review.
Multiple doses of physostigmine in healthy volunteers did not block the effect of a single drop of latanoprost during a 1-day study. One study attempting to find the optimal timing of administration of latanoprost and pilocarpine claimed to show that additivity was …
Multiple doses of physostigmine in healthy volunteers did not block the effect of a single drop of latanoprost during a 1-day study. …
Latanoprost for the treatment of pediatric glaucoma.
Enyedi LB, Freedman SF. Enyedi LB, et al. Surv Ophthalmol. 2002 Aug;47 Suppl 1:S129-32. doi: 10.1016/s0039-6257(02)00303-x. Surv Ophthalmol. 2002. PMID: 12204709 Review.
Latanoprost is a prostaglandin F(2alpha) analog that reduces intraocular pressure (IOP) by 20-40% in adults with open-angle glaucoma or ocular hypertension. ...Most of the patients in these studies showed disappointingly little IOP effect from this drug, but some children, …
Latanoprost is a prostaglandin F(2alpha) analog that reduces intraocular pressure (IOP) by 20-40% in adults with open-angle glaucoma …
Latanoprost as a new horizon in the medical management of glaucoma.
Stjernschantz J, Alm A. Stjernschantz J, et al. Curr Opin Ophthalmol. 1996 Apr;7(2):11-7. doi: 10.1097/00055735-199604000-00003. Curr Opin Ophthalmol. 1996. PMID: 10163315 Review.
Latanoprost is a new prostaglandin F2 alpha analogue specifically developed for the treatment of glaucoma. Latanoprost is a selective FP receptor agonist, with a primary mode of action of increased uveoscleral outflow of aqueous humor. ...
Latanoprost is a new prostaglandin F2 alpha analogue specifically developed for the treatment of glaucoma. Latanoprost is a se …
Latanoprost-loaded phytantriol cubosomes for the treatment of glaucoma.
Bessone CDV, Akhlaghi SP, Tártara LI, Quinteros DA, Loh W, Allemandi DA. Bessone CDV, et al. Eur J Pharm Sci. 2021 May 1;160:105748. doi: 10.1016/j.ejps.2021.105748. Epub 2021 Feb 7. Eur J Pharm Sci. 2021. PMID: 33567324
Latanoprost concentration in the formulations ranged from 0.00125% to 0.02% w/v. ...Calorimetric studies revealed a fast and exothermic interaction between latanoprost and cubosomes. According to in vitro essays, latanoprost release from cubosomes was slow in …
Latanoprost concentration in the formulations ranged from 0.00125% to 0.02% w/v. ...Calorimetric studies revealed a fast and exotherm …
2,258 results

Searches related to "latanoprost"